Goldline Pharmaceutical Limited IPO — Explained
IPO Overview
Founded on February 28, 2005, by pharmacy graduate Mr. Amol Mujumdar, Goldline Pharmaceutical Limited is a Nagpur-based, fast-growing pharmaceutical marketing company operating across 5 segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The company is engaged in the business of marketing pharmaceutical products under its proprietary “Goldline” brand. The products are not manufactured in-house — instead, the company enters into agreements with third-party manufacturers who produce these products based on market research and specifications. Once manufactured, the products are sold under the “Goldline” brand to distributors, retailers, and wholesalers.
Goldline Pharmaceutical has a wide product range sold across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. The company is now launching its SME IPO on the BSE SME platform. The IPO is an SME book-built issue of ₹11.61 crore, comprising entirely a fresh issue of 27 lakh shares, with no offer-for-sale component. The IPO opens for subscription on 12 May 2026 and closes on 14 May 2026, with listing proposed on BSE SME on 19 May 2026.
IPO Detailed Information
Issue Details
| Parameter | Details |
| IPO Type | Book Built – SME |
| Listing Exchange | BSE SME |
| IPO Open Date | 12 May 2026 |
| IPO Close Date | 14 May 2026 |
| Allotment Date | 15 May 2026 (Expected) |
| Refund Initiation | 16 May 2026 |
| Credit to Demat | 16 May 2026 |
| Listing Date | 19 May 2026 (Tentative) |
| Price Band | ₹41 – ₹43 per share |
| Face Value | ₹10 per share |
| Lot Size | 3,000 shares |
| Minimum Investment (Retail) | ₹2,58,000 (2 lots = 6,000 shares) |
| Minimum Investment (HNI) | ₹3,87,000 (3 lots = 9,000 shares) |
| Issue Size | ₹11.61 crore |
| Fresh Issue | 27,00,000 shares (₹11.61 crore) |
| Offer For Sale (OFS) | Nil |
Note: The entire IPO is a fresh issue — no offer-for-sale component. All proceeds go directly to the company.
Issue Break-up
| Category | Allocation |
| Qualified Institutional Buyers (QIB) | ~50% |
| Non-Institutional Investors (NII/HNI) | ~15% |
| Retail Individual Investors (RII) | ~35% |
| Market Maker | Reserved Portion |
OFS / Selling Shareholders
There is no Offer For Sale (OFS) in this IPO. The entire issue is a fresh issue, and all IPO proceeds will flow directly to the company.
Objects of the Issue (Fund Utilization)
The proceeds of ₹8.90 crore will be used towards repayment and/or prepayment of existing borrowings taken by the company. The remaining funds will be utilized towards general corporate purposes.
- Repayment / prepayment of existing borrowings — ₹8.90 crore
- General corporate purposes — remaining proceeds
Lead Managers & Registrar
- Book Running Lead Manager: Cumulative Capital Pvt. Ltd.
- Registrar to the Issue: Bigshare Services Pvt. Ltd.
- Market Maker: Nirman Share Brokers
Promoters & Management
Mr. Amol Laxmikant Mujumdar, aged 54 years, is the Promoter, Chairman, and Managing Director of the company. He holds 27,49,988 equity shares, representing 39.85% of pre-offer equity capital. Mr. Swapan Premprakash Khandelwal, aged 57 years, is the Promoter and Whole-Time Director of the company. He also holds 27,49,988 equity shares, representing 39.85% of pre-offer equity capital.
The promoters and key management personnel collectively bring more than 5 decades of combined industry experience in pharmaceutical marketing, distribution, and business development.
Company Details
Established in 2005, Goldline Pharmaceutical is engaged in marketing pharmaceutical products under the “Goldline” brand across segments like general medicine, cardiology, diabetology, pediatrics, and wellness. The company follows an asset-light business model by outsourcing manufacturing to third-party pharma manufacturers while focusing on branding and distribution. Goldline has a strong presence across multiple Indian states, with operations mainly based in Nagpur, Maharashtra.
Sectors / Therapeutic Segments:
- General Medicine (Goldline Pharma)
- Cardiology (Goldline Cardinal)
- Diabetology & Ayurveda (Goldline Aayushman)
- Wellness & Nutraceuticals (Goldline InLife)
- Specialty Healthcare (Goldline Wellness)
Key Business Model:
- The company does not own or operate any manufacturing facility. It relies on 15 third-party contract manufacturers who produce products based on the company’s market research, demand analysis, and specifications. Products are distributed through 8 distributors, with credit terms of 60 days extended to distributors.
Geographic Presence:
- Geographic focus is concentrated in Maharashtra and Madhya Pradesh, which together account for over 70% of revenue. Presence also in Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Financial Snapshot
| Period | Revenue (₹ Cr) | PAT (₹ Cr) |
| FY24 | ₹23.57 | ₹1.81 |
| FY25 | ₹28.06 | ₹2.83 |
Key Financial Metrics
- Revenue grew at approximately 19% per annum, with ROE improving to 27.34% in FY25 and debt-to-equity declining to 1.54x.
- Total borrowings stood at ₹913.78 lakhs as of March 31, 2026, with promoters as co-borrowers on unsecured loans totalling ₹1.67 crore.
- Industry P/E: 7.57x – 28.94x, average 18.26x
Company Strengths
- Competitive strengths include experienced promoters, scalable operations, diversified product categories, established distributor relationships, and a growing healthcare network presence.
- Asset-light business model — no manufacturing capex required, enabling lean operations and scalability
- Consistent revenue growth of ~19% per annum and improving ROE of 27.34% in FY25 are key positives.
- Strong multi-state distribution reach across 7 Indian states with a diversified therapeutic portfolio
- Entire IPO is a fresh issue — no promoter exit, all funds going into debt reduction and corporate use
- Well-established long-term relationships with suppliers and vendors for raw material support.
Key Risks & Challenges
- Related-party revenue dependency — promoter group entities (Numerius Healthcare, Nucleage Lifescience, and Nucleage Pharma Solutions) collectively contributed 22.04% of the company’s revenue as distributors, indicating significant related-party dependency alongside potential conflicts of interest.
- Complete manufacturing dependency on 15 third-party contract manufacturers, with no in-house production capability, creating supply chain and quality control risks.
- Geographic concentration — Maharashtra and Madhya Pradesh account for over 70% of revenue, making the business vulnerable to regional slowdowns.
- Outstanding litigation exposure includes ₹271.23 lakhs in direct tax matters, ₹63.70 lakhs in indirect tax matters, and ₹7.75 lakhs in regulatory actions.
- Regulatory compliance lapses — late fees totalling over ₹1.5 lakhs for ROC filing delays and late fees of ₹25,000+ for GST payment delays.
- Small scale of operations at ₹28.06 crore revenue limits competitive positioning against established pharma players
Disclaimer:
This document is for informational purposes only and should not be considered as investment advice. Investors should read the Red Herring Prospectus (RHP) carefully and consult a financial advisor before investing in any IPO. Market investments are subject to risk.
